| Latest Encysive Pharmaceuticals News Headlines |
| Date | Time | Source | |
| 04/03/2008 | 4:46PM | PRNUS | QED International Associates Announces Changes to the HealthShares(TM) Respiratory Pulmonary Index and the HealthShares(TM) Comp
NEW YORK, April 3, 2008 /PRNewswire/ -- QED International Associates Inc, administrator for the HealthShares(TM) Indexes, a series of 20 underlying indexes for the HealthShares(TM) Exchange-Traded Funds, today announced that effective at the opening of trading on Monday April 7, 2008 Perrigo Company (NASDAQ:PRGO) will... More...>> |
| 02/21/2008 | 9:48AM | PRNUS | BeaconEquity.com Issues TraderNotes on MTTG, ENCY, RIMM, DRYS, SPWR
DALLAS, Feb. 21 /PRNewswire/ -- BeaconEquity.com announces the availability of TraderNotes on stocks that are making news today.
Investors can view all of the daily trading notes for free by visiting: http://www.beaconequity.com/ -- Click on TraderNotes.
Today's TraderNotes include: Material Technologies, Inc. (OTC:MTTG... More...>> |
| 10/24/2006 | 7:00AM | PRNUS | Encysive Pharmaceuticals Announces Presentations/Webcasts at C.E. Unterberg Towbin, Rodman & Renshaw, and Cowen & Co. Conference
HOUSTON, Oct. 24 /PRNewswire-FirstCall/ -- Encysive Pharmaceuticals (NASDAQ:ENCY) today announced that Bruce D. Given, M.D., President and Chief Executive Officer, will present a corporate overview at three upcoming health care conferences: the C.E. Unterberg, Towbin Life Sciences Conference; Rodman & Renshaw 8th Annual... More...>> |
| 10/24/2006 | 7:00AM | PRNUS | Encysive Pharmaceuticals Announces Presentations/Webcasts at C.E. Unterberg Towbin, Rodman & Renshaw, and Cowen & Co. Conference
HOUSTON, Oct. 24 /PRNewswire-FirstCall/ -- Encysive Pharmaceuticals (NASDAQ:ENCY) today announced that Bruce D. Given, M.D., President and Chief Executive Officer, will present a corporate overview at three upcoming health care conferences: the C.E. Unterberg, Towbin Life Sciences Conference; Rodman & Renshaw 8th Annual... More...>> |
| 10/10/2006 | 7:00PM | PRNUS | Shareholder Class Action Filed Against Encysive Pharmaceuticals Inc. by the Law Firm of Schiffrin & Barroway, LLP
RADNOR, Pa., Oct. 10 /PRNewswire/ -- The following statement was issued today by the law firm of Schiffrin & Barroway, LLP:
Notice is hereby given that a class action lawsuit was filed in the United States District Court for the Southern District of Texas on behalf of all securities purchasers of Encysive Pharmaceuticals... More...>> |
| 10/04/2006 | 5:18PM | PRNUS | Federman & Sherwood Announces That a Securities Class Action Lawsuit Has Been Filed Against Encysive Pharmaceuticals Inc.
OKLAHOMA CITY, Oct. 4 /PRNewswire/ -- On September 26, 2006, a class action lawsuit was filed in the United States District Court for the Southern District of Texas against Encysive Pharmaceuticals Inc. (NASDAQ:ENCY). The complaint alleges violations of federal securities laws, Sections 10(b) and 20(a) of the Securities... More...>> |
| 08/02/2006 | 6:00AM | PRNUS | Mentus Creativity, Experience Proves Winning Combination for Record 12 LACP Annual Report Awards
Invitrogen and Leap Wireless Secure Top 100 Rankings
SAN DIEGO, Aug. 2 /PRNewswire/ -- Mentus, a San Diego-based integrated marketing communications and design agency, announced today that the annual reports for twelve of its clients have been bestowed with the prestigious LACP 2005 Vision Award in the international... More...>> |
| 07/24/2006 | 7:02PM | PRNUS | FDA Issues Approvable Letter for THELIN(TM) (Sitaxsentan Sodium); One Outstanding Item Remains
Conference Call Scheduled for Tuesday, July 25 at 8:00 a.m. ET
HOUSTON, July 24 /PRNewswire-FirstCall/ -- Encysive Pharmaceuticals (NASDAQ:ENCY) today announced that at 4:35 p.m. ET the Company received an approvable letter from the U.S. Food and Drug Administration (FDA) for THELIN(TM) (sitaxsentan sodium), which is... More...>> |
| 06/26/2006 | 4:09PM | PRNUS | Encysive Pharmaceuticals Announces Clinical Organizational Changes
HOUSTON, June 26 /PRNewswire-FirstCall/ -- Encysive Pharmaceuticals (NASDAQ:ENCY) today announced changes to the Company's clinical organizational structure, in keeping with its commercialization-focused strategy.
Under the revised clinical structure, medical affairs functions will report to George W. Cole, the Company's... More...>> |
| 06/22/2006 | 5:02AM | PRNUS | Encysive Pharmaceuticals Announces Presentation of New STRIDE-2X Data at EULAR Congress
HOUSTON, June 22 /PRNewswire-FirstCall/ -- Encysive Pharmaceuticals (NASDAQ:ENCY) today announced the presentation of new STRIDE-2X data evaluating Thelin(TM) (sitaxsentan sodium) in pulmonary arterial hypertension (PAH) at the European League Against Rheumatism (EULAR) Annual European Congress of Rheumatology in Amsterdam... More...>> |
| 06/15/2006 | 12:41PM | PRNUS | FDA Grants Class 1 Review to Encysive Pharmaceuticals' Complete Response to Thelin(TM) (Sitaxsentan Sodium) New Drug Applicatio
Agency Assigns 60-Day PDUFA Target Action Date
HOUSTON, June 15 /PRNewswire-FirstCall/ -- Encysive Pharmaceuticals (NASDAQ:ENCY) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Company's complete response to the March 24 approvable letter regarding its New Drug Application... More...>> |
| 06/02/2006 | 6:26AM | PRNUS | Encysive Pharmaceuticals' Thelin(TM) (sitaxentan sodium) Receives Positive Opinion From European Authorities
HOUSTON, June 2 /PRNewswire-FirstCall/ -- Encysive Pharmaceuticals (NASDAQ:ENCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Agency for the Evaluation of Medicinal Products (EMEA) issued a positive opinion recommending the approval of Thelin(TM) (sitaxentan sodium... More...>> |
| 05/25/2006 | 6:30AM | PRNUS | Encysive Pharmaceuticals Submits Complete Response to FDA for Thelin(TM) New Drug Application
HOUSTON, May 25 /PRNewswire-FirstCall/ -- Encysive Pharmaceuticals (NASDAQ:ENCY) today announced the submission of a complete response to the concerns and observations as noted in the March 24 approvable letter issued by the U.S. Food and Drug Administration (FDA) regarding the Company's New Drug Application (NDA) for... More...>> |
| 05/10/2006 | 7:00AM | PRNUS | Encysive Pharmaceuticals Reports First Quarter 2006 Financial Results; Conference Call Scheduled for Today at 8:00 a.m. Eastern
HOUSTON, May 10 /PRNewswire-FirstCall/ -- Encysive Pharmaceuticals (NASDAQ:ENCY) today announced financial results for the first quarter ended March 31, 2006. A key event in the first quarter was the receipt of an approvable letter for Thelin(TM) (sitaxsentan sodium) from the U.S. Food and Drug Administration (FDA).
"We... More...>> |
| 05/01/2006 | 2:30PM | PRNUS | Encysive Pharmaceuticals Announces Conference Call to Discuss First Quarter 2006 Results
HOUSTON, May 1 /PRNewswire-FirstCall/ -- Encysive Pharmaceuticals (NASDAQ:ENCY) will hold an investor conference call on Wednesday, May 10, 2006 at 8:00 a.m. ET to discuss its first quarter 2006 financial results.
You may access the call either through the call-in number below or through the audio webcast. The access... More...>> |
| 04/20/2006 | 8:00AM | PRNUS | Encysive Pharmaceuticals Announces Presentations/Webcasts at UBS, Deutsche Bank and Rodman & Renshaw Conferences
HOUSTON, April 20 /PRNewswire-FirstCall/ -- Encysive Pharmaceuticals (NASDAQ:ENCY) today announced that the Company will be presenting a corporate overview at three upcoming health care conferences: the UBS Global Specialty Pharmaceuticals Conference, Deutsche Bank 31st Annual Health Care Conference, and Rodman & Renshaw... More...>> |
| 03/24/2006 | 8:16PM | PRNUS | Encysive Pharmaceuticals Receives Approvable Letter From FDA for Thelin; Conference Call Scheduled for Monday, March 27th at 7:
HOUSTON, March 24 /PRNewswire-FirstCall/ -- Encysive Pharmaceuticals (NASDAQ:ENCY) today announced that the Company has received an approvable letter from the U.S. Food and Drug Administration (FDA) for Thelin(TM) (sitaxsentan sodium), which is under review for the treatment of pulmonary arterial hypertension (PAH... More...>> |
| 03/23/2006 | 5:52PM | PRNUS | Encysive Pharmaceuticals Delays Studies With TBC3711
HOUSTON, March 23 /PRNewswire-FirstCall/ -- Encysive Pharmaceuticals (NASDAQ:ENCY) today announced that Encysive and the U.S. Food and Drug Administration (FDA) have placed TBC3711, the Company's next-generation selective endothelin receptor antagonist entering early clinical studies, on clinical hold. The hold is... More...>> |
| 03/20/2006 | 7:30AM | PRNUS | Encysive Pharmaceuticals Appoints Vice President of European Operations
HOUSTON, March 20 /PRNewswire-FirstCall/ -- Encysive Pharmaceuticals, Inc. (NASDAQ:ENCY) today announced the appointment of Thierry A. Plouvier, M.D., as Vice President, European Operations, a new position within the Company. Dr. Plouvier will oversee operations in the European Union, including sales and marketing... More...>> |
| 03/03/2006 | 7:30AM | PRNUS | Encysive Pharmaceuticals Announces Retirement of Frank C. Carlucci from Board of Directors
HOUSTON, March 3 /PRNewswire-FirstCall/ -- Encysive Pharmaceuticals (NASDAQ:ENCY) today announced that Frank C. Carlucci will not stand for re- election and plans to retire from the Company's Board of Directors, effective at the 2006 Annual Stockholders meeting to be held on May 12, 2006. He has served as a member... More...>> |